Postmarketing adverse events of tamoxifen in male and female patients with breast cancer
{{output}}
Tamoxifen (TAM), a selective estrogen receptor (ER) modulator, has received approval for use in patients with breast cancer (BC) exhibiting positive ER expression. Given the widespread clinical use of TAM, a comprehensive real-world study of its adverse events... ...
